Brokerage firm Chardan Capital Maintains its rating on Regulus Therapeutics Inc(NASDAQ:RGLS). In a research note issued to the investors, the brokerage major Raises the price-target to $20.00 per share. The shares have been rated Buy. The rating by Chardan Capital was issued on Jun 7, 2016.
Regulus Therapeutics Inc (RGLS) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -1.31% at a volume of 5,83,968. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.32. The peak price level was also seen at $5.32 while the days lowest was $5.13. Finally the shares closed at $5.27. The 52-week high of the shares is $11.59 while the 52-week low is $4.96. According to the latest information available, the market cap of the company is $278 M.
Regulus Therapeutics Inc(RGLS) last announced its earnings results on May 2, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $489.00K. Analysts had an estimated revenue of $2.62M. Earnings per share were $-0.40. Analysts had estimated an EPS of $-0.33.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Joseph P Hagan (COO) purchased 10,000 shares at $7.19 per share price.Also, On Aug 13, 2015, Mark G Foletta (director) purchased 10,000 shares at $7.64 per share price.On Jul 21, 2015, William H Rastetter (director) purchased 100,000 shares at $10.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease which is designed to support its therapeutic pipeline collaborators and strategic partners. Its development programs include microRNA target miR-122 miR-21 RG-012 miR-103/107 miR-19 miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.